BDX — BCAL Diagnostics Income Statement
0.000.00%
Last trade - 00:00- AU$21.96m
- AU$19.81m
- AU$2.65m
Annual income statement for BCAL Diagnostics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.275 | 0.7 | 2.79 | 3.05 | 2.65 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1.8 | 4.1 | 7.9 | 9.4 | 9.98 |
| Operating Profit | -1.53 | -3.4 | -5.11 | -6.35 | -7.33 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -1.52 | -3.39 | -5.06 | -6.4 | -7.24 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.52 | -3.39 | -5.06 | -6.4 | -7.24 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.52 | -3.39 | -5.06 | -6.4 | -7.24 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.52 | -3.39 | -5.06 | -6.4 | -7.24 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.005 | -0.016 | -0.024 | -0.025 | -0.02 |